Spyryx Biosciences

OverviewSuggest Edit

Spyryx Biosciences is a biopharmaceutical company which provides peptide therapeutics for obstructive lung diseases. The Company focuses on cystic fibrosis and obstructive pulmonary diseases. Its main product is spx-101 which replaces splunc1 in cf to restore airway hydration.
TypePrivate
Founded2013
HQDurham, NC, US
Websitespyryxbio.com

Latest Updates

Employees (est.) (Oct 2021)1
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Spyryx Biosciences

Tim Shannon

Tim Shannon

Chair
Timm Crowder

Timm Crowder

COO
Show more

Spyryx Biosciences Office Locations

Spyryx Biosciences has an office in Durham
Durham, NC, US (HQ)
801 Capitola Dr
Show all (1)

Spyryx Biosciences Financials and Metrics

Summary Metrics

Founding Date

2013

Spyryx Biosciences total Funding

$18.2 m

Spyryx Biosciences latest funding size

$18.2 m

Time since last funding

6 years ago

Spyryx Biosciences investors

Spyryx Biosciences's latest funding round in May 2015 was reported to be $18.2 m. In total, Spyryx Biosciences has raised $18.2 m
Show all financial metrics

Spyryx Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Spyryx Biosciences Online and Social Media Presence

Embed Graph

Spyryx Biosciences Blogs

Without getting too complex, it [SPX-101] helps patients clear mucus from their lungs.

11. Jun / Monday Morning Thoughts – Blog Post by Gunnar Esiason A few medications are charging through the drug pipeline that could one day, very soon, broadly impact the CF community. First we have this guy, SPX-101. SPX-101 is an ENaC Modulator. Without getting too complex, it helps patients clear…

SPX-101 is Stable In and Retains Function After Exposure to Cystic Fibrosis Sputum

The science team at Spyryx has recently published an open-access article in the Journal of Cystic Fibrosis, supporting the stability of SPX-101 in the protease-rich environment of cystic fibrosis airways. Here, we demonstrate SPLUNC1, the natural allosteric regulator of ENaC, is degraded by multiple…

Phase 2 Study Shows Promising Results for Potential Mucus Clearance Drug

A new drug intended to make it easier to clear mucus from the lungs of people with cystic fibrosis showed promising results in a Phase 2 clinical trial. The drug, called SPX-101, blocks the overactive sodium channels that line CF lung cells. – Published on June 7, 2018 | Cystic Fibrosis Foundation® …

Spyryx SPX-101 Phase 2 HOPE-1 Trial Shows Improvement in Lung Function in Patients with Cystic Fibrosis via Novel Modulation of ENaC

Inhaled drug can be used regardless of a patient’s particular CF mutation. – DURHAM, N.C., June 6, 2018 /PRNewswire/ — Today Spyryx shared positive data for the first cohort of the SPX-101 Phase 2 clinical trial HOPE-1 (Hydration for Optimal Pulmonary Effectiveness), which showed that treatment with…

Spyryx Biosciences Frequently Asked Questions

  • When was Spyryx Biosciences founded?

    Spyryx Biosciences was founded in 2013.

  • Who are Spyryx Biosciences key executives?

    Spyryx Biosciences's key executives are Tim Shannon and Timm Crowder.

  • How many employees does Spyryx Biosciences have?

    Spyryx Biosciences has 1 employees.

  • Who are Spyryx Biosciences competitors?

    Competitors of Spyryx Biosciences include Pacific Medical Centers, Verve Therapeutics and Stealth BioTherapeutics.

  • Where is Spyryx Biosciences headquarters?

    Spyryx Biosciences headquarters is located at 801 Capitola Dr, Durham.

  • Where are Spyryx Biosciences offices?

    Spyryx Biosciences has an office in Durham.

  • How many offices does Spyryx Biosciences have?

    Spyryx Biosciences has 1 office.